The NCT Neurooncology Program has a leading position nationally in terms of brain tumor patient numbers (473 in 2009), trial enrolment and activity (Wolfgang Wick, Chair EORTC Brain Tumor Group). DKFZ research findings (Martin-Villalba – Cancer Cell 2008) translate into a first-in-man clinical trial (Wick, Debus). The German ICGC at DKFZ targets pediatric brain tumors. Program project grants implement molecular profiling into diagnosis therapies in adult glioma (NGFNplus), and anaplastic gliomas (BMBF Network Molecular Diagnostics). Isocitrate dehydrogenase 1 was validated as a prognostic marker in glioma (Wick, JCO 2009) and a glioblastoma trial based on molecular (MGMT) stratification (Hartmann, Wick, Debus) was completed. NCT translational research has a key role in the tissue-based German Glioma Network (GGN; Hartmann, von Deimling). An endowed professorship (Hornbach Holding) will support the NCT Clinical Program in Brain Tumors.
NCT Clinical Cancer Program in Brain Cancer
- Develop an oligogene signature (von Deimling, JCO 2009), including novel epigenetic markers using methylated DNA binding-domain proteins (MBDs) and sequence-specific mass spectrometry (MassARRAY).
- Generate a database building on the individual genomic and proteomic information of the Gene Glioma Network for the German Translational Oncology Consortium.
- Implement an oncolytic parvovirus H1 trial in glioblastoma patients; generate novel oncolytic viruses in cooperation with the Translational Oncology Department and PEI.
- Design molecularly stratified trials (e.g., TGF-•/Notch/mTOR targets) with targeted substances, translating novel research findings into clinical practice.